YAP1 and neoplasm: In a murine model of cholangiocarcinoma driven by YAP/AKT, VP treatment reduced tumor burden and modulated the immune microenvironment, increasing the ratio of antitumor M1 TAMs to protumor M2 TAMs and boosting the activation of CD8+ T cells75.